📊 AYTU Key Takeaways
Is Aytu Biopharma, Inc. (AYTU) a Good Investment?
AYTU BioPharma faces severe profitability challenges with a -29.7% net margin and negative operating income despite 64.7% gross margins, indicating significant operational inefficiencies or high R&D/SG&A costs. While the company maintains adequate liquidity with $30M cash and positive free cash flow of $3M, the persistent losses combined with negative ROE (-60.7%) and ROA (-7.1%) suggest the current business model is not generating value for shareholders. The marginal 1.8% revenue growth fails to offset deteriorating bottom-line performance, raising sustainability concerns.
AYTU Biopharma shows solid gross profitability and positive free cash flow, but those strengths are outweighed by persistent operating and net losses, weak interest coverage, and a thin equity base. Revenue growth is minimal, so the current cash generation needs to prove durable rather than temporary, especially given the company’s negative margins and constrained balance sheet flexibility.
Why Buy Aytu Biopharma, Inc. Stock? AYTU Key Strengths
- Strong gross margin of 64.7% indicates solid pricing power and product-market fit at the production level
- Positive operating cash flow of $3.1M and free cash flow of $10.5M FCF margin provide near-term liquidity runway
- Adequate cash position of $30M with current ratio of 1.16x supports short-term operational needs
- Manageable debt/equity ratio of 0.70x indicates reasonable leverage levels
- Gross margin of 64.7% indicates the core product portfolio has reasonable pricing power and favorable unit economics before overhead
- Operating cash flow of $3.06M and free cash flow of $3.04M provide near-term liquidity support despite accounting losses
- Cash balance of $30.02M and quick ratio of 1.03x suggest the company can currently meet near-term obligations without severe immediate stress
AYTU Stock Risks: Aytu Biopharma, Inc. Investment Risks
- Persistent net losses (-$8.6M) and negative operating margins (-12%) demonstrate the company is destroying shareholder value operationally
- Severely negative ROE (-60.7%) indicates equity is being eroded; current equity of $14.2M is inadequate relative to $122M asset base
- Minimal revenue growth of 1.8% YoY insufficient to achieve profitability or scale; company may lack competitive momentum
- Negative interest coverage ratio (-1.7x) indicates inability to service debt from operating earnings; reliant on cash reserves
- Zero insider trading activity in last 90 days may suggest lack of confidence from management
- Operating margin of -12.0% and net margin of -29.7% show the business is still not sustainably profitable
- ROE of -60.7% and stockholders equity of only $14.20M indicate a weak capital base relative to losses and liabilities
- Interest coverage of -1.7x and current ratio of 1.16x leave limited room if cash flow weakens or financing conditions tighten
Key Metrics to Watch
- Operating margin trend - critical to assess if company can reach profitability
- Quarterly revenue growth rate - currently anemic at 1.8% YoY
- Cash burn rate and cash runway - $30M cash must sustain operations if losses continue
- Gross margin sustainability - verify 64.7% margin is maintained as revenue scales
- R&D efficiency and pipeline progress - understand why operating costs exceed gross profit
- Sustained improvement in operating income and operating margin
- Operating cash flow quality versus net losses, including working capital dependence
Aytu Biopharma, Inc. (AYTU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Aytu Biopharma, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
AYTU Profit Margin, ROE & Profitability Analysis
AYTU vs Healthcare Sector: How Aytu Biopharma, Inc. Compares
How Aytu Biopharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Aytu Biopharma, Inc. Stock Overvalued? AYTU Valuation Analysis 2026
Based on fundamental analysis, Aytu Biopharma, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Aytu Biopharma, Inc. Balance Sheet: AYTU Debt, Cash & Liquidity
AYTU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Aytu Biopharma, Inc.'s revenue has shown modest growth of 1% over the 5-year period. The most recent EPS of $-74.01 indicates the company is currently unprofitable.
AYTU Revenue Growth, EPS Growth & YoY Performance
AYTU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $15.2M | $788.0K | $-0.26 |
| Q1 2026 | $13.9M | $1.5M | $-0.08 |
| Q3 2025 | $14.0M | -$220.0K | $0.21 |
| Q2 2025 | $16.2M | -$220.0K | $-0.04 |
| Q1 2025 | $16.6M | $1.5M | $-0.15 |
| Q3 2024 | $18.0M | -$220.0K | N/A |
| Q2 2024 | $22.9M | -$220.0K | N/A |
| Q1 2024 | $22.1M | -$701.0K | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Aytu Biopharma, Inc. Dividends, Buybacks & Capital Allocation
AYTU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Aytu Biopharma, Inc. (CIK: 0001385818)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AYTU
What is the AI rating for AYTU?
Aytu Biopharma, Inc. (AYTU) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AYTU's key strengths?
Claude: Strong gross margin of 64.7% indicates solid pricing power and product-market fit at the production level. Positive operating cash flow of $3.1M and free cash flow of $10.5M FCF margin provide near-term liquidity runway. ChatGPT: Gross margin of 64.7% indicates the core product portfolio has reasonable pricing power and favorable unit economics before overhead. Operating cash flow of $3.06M and free cash flow of $3.04M provide near-term liquidity support despite accounting losses.
What are the risks of investing in AYTU?
Claude: Persistent net losses (-$8.6M) and negative operating margins (-12%) demonstrate the company is destroying shareholder value operationally. Severely negative ROE (-60.7%) indicates equity is being eroded; current equity of $14.2M is inadequate relative to $122M asset base. ChatGPT: Operating margin of -12.0% and net margin of -29.7% show the business is still not sustainably profitable. ROE of -60.7% and stockholders equity of only $14.20M indicate a weak capital base relative to losses and liabilities.
What is AYTU's revenue and growth?
Aytu Biopharma, Inc. reported revenue of $29.1M.
Does AYTU pay dividends?
Aytu Biopharma, Inc. does not currently pay dividends.
Where can I find AYTU SEC filings?
Official SEC filings for Aytu Biopharma, Inc. (CIK: 0001385818) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AYTU's EPS?
Aytu Biopharma, Inc. has a diluted EPS of $-0.89.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AYTU a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Aytu Biopharma, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AYTU stock overvalued or undervalued?
Valuation metrics for AYTU: ROE of -60.7% (sector avg: 15%), net margin of -29.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AYTU stock in 2026?
Our dual AI analysis gives Aytu Biopharma, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AYTU's free cash flow?
Aytu Biopharma, Inc.'s operating cash flow is $3.1M, with capital expenditures of $17.0K. FCF margin is 10.5%.
How does AYTU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -29.7% (avg: 12%), ROE -60.7% (avg: 15%), current ratio 1.16 (avg: 2).